Robert Iannone, EVP, Global Head of R&D & CMO at Jazz Pharmaceuticals plc (JAZZ), sold 17,851 shares at $138.21 ($2.5M) on 2025-03-07, disclosed to the SEC on 2025-03-07.
Scheduled sale ($2.5M) by EVP, Global Head of R&D & CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $138.95 | 5,239 | $728K | 29.4% |
| 2 | $138.21 | 5,532 | $765K | 30.9% |
| 3 | $138.21 | 5,532 | $765K | 30.9% |
| 4 | $140.00 | 1,548 | $217K | 8.8% |
| Total | $138.58 avg | 17,851 | $2.5M | 100% |
| Filing → |
| JAZZ | SELL | 2025-03-12 | $665K | — | Filing → |
| JAZZ | SELL | 2022-12-13 | $559K | — | Filing → |